Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 mai 2025 04h03 HE | Source: Research and Markets

Denosumab Market Report 2025-2029 & 2034: Strategic Collaborations and Digital Health Pave the Way for Innovations, First-Line Treatment Boyoubei Gains Traction

Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Denosumab Market Report 2025" has been added to ResearchAndMarkets.com's offering. The denosumab market has experienced robust growth, increasing...
24 oct. 2024 09h55 HE | Source: Research and Markets

Denosumab (Prolia & Xgeva) by Amgen Biosimilars Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic...
08 oct. 2024 07h00 HE | Source: Teva Pharmaceutical Industries Ltd

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal womenTVB-009P, Teva’s proposed biosimilar to Prolia, showed...
01 févr. 2021 06h38 HE | Source: Research and Markets

Global Osteoporosis Disease Analysis Market Report 2020: Novartis has the Highest Number of Completed Clinical Trials for Osteoporosis with 120 Trials

Dublin, Feb. 01, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Osteoporosis" report has been added to ResearchAndMarkets.com's offering. Osteoporosis is the most common metabolic bone disease, and...